Antifibrinolytic agents in current anaesthetic practice

British Journal of Anaesthesia

Volumn 111, Issue 4, 2013, Pages 549-563

  Ortmann, E ^a   Besser, M W ^b   Klein, A A ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antifibrinolytic agents; Cardiac surgical procedures; Hepatectomy; Intracranial haemorrhages; Liver transplantation; Orthopaedics; Post partum haemorrhage; Postoperative haemorrhage; Wounds and injuries

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; PLACEBO; PLASMIN INHIBITOR; TRANEXAMIC ACID;

ARTICLE; CLINICAL TRIAL; GYNECOLOGIC SURGERY; HEART SURGERY; HUMAN; INJURY; LIVER SURGERY; NEUROSURGERY; NONHUMAN; OBSTETRIC OPERATION; OFF PUMP CORONARY SURGERY; ORTHOPEDIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; TISSUE INJURY;

EID: 84888228700     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet154     Document Type: Review

References (115)

1. Mehta RH, Sheng S, O'Brien SM, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes 2009; 2: 583-90
2. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116: 2544-52
3. Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol 2009; 26: 722-9
4. Gomez K, Tuddenham EGD, McVey JH. Normal haemostasis. In: Hoffbrand AV, Catovsky D, Tuddenham EGD, eds. Postgraduate Haematology. Oxford: Wiley-Blackwell, 2011
5. Hedner U, Hirsch J, Marder V. Therapy with Antifibrinolytic Agents. In: ColmanRW, Hirsch J, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis : Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 2001
6. DietrichW. Reducing thrombinformation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996; 27 (Suppl. 1): S50-7
7. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033-41
8. Turkoz A, Cigli A, But K, et al. The effects of aprotininandsteroidson generation of cytokines during coronary artery surgery. J Cardiothorac Anesth 2001; 15: 603-10
9. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003; 126: 1498-503
10. Dorman BH, Stroud RE, Wyckoff MM, et al. Differential effects of epsilon-aminocaproic acidand aprotinin onmatrix metalloproteinase release in patients following cardiopulmonary bypass. J Cardiovasc Pharmacol 2008; 51: 418-23
11. Hill GE, Alonso A, Spurzem JR,Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658-62
12. Greilich PE,Okada K, LathamP, KumarRR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation 2001; 104: I265-9
13. Homi HM, Sheng H, Arepally GM, Mackensen GB, Grocott HP. Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. Anesth Analg 2010; 111: 38-45
14. Brown JR, Toler AW, Kramer RS, Landis RC. Anti-inflammatory effect of aprotinin: a meta-analysis. J Extra Corpor Technol 2009; 41: 79-86
15. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open- heart surgery. Lancet 1987; 2: 1289-91
16. DietrichW, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in zardiac surgery. Ann Thorac Surg 2007; 84: 1144-50
17. SedrakyanA, Treasure T, Elefteriades JA. Effect of aprotininonclinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-8
18. ManganoDT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65
19. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31
20. HenryDA, Carless PA,Moxey AJ, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; 1: CD001886
21. Health Canada. Health Canada decision on Trasylol (aprotinin). Available from http://www.hc-sc.gc.ca/ahc-asc/media/advisoriesavis/-2011/2011-124-eng.php (accessed 7 April 2012)
22. Bayer-Inc.-Canada. Health Canada Endorsed Important Safety Information on TRASYLOLw (aprotinin). 2011
23. European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin: review finds that benefits of all antifibrinolytic medicines outweigh risks in restricted range of indications. Available from http://www.ema.europa.eu/ema/pages/news-and-events/news/2012/02/ news-detail-001447.jsp (accessed 7 April 2012)
24. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; 4: CD001886
25. Okamoto S. British Patent Specification No. 770,693. London: Her Majesty's Stationery Office, 1957
26. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61
27. Coleman R, Hirsch J, Marder V, Clowes A, George J. Hemostasis and Thrombosis, Principles and Practice, 4th edn. Philadelphia: Lippincott Williams, 2000
28. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063-70
29. Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg 1996; 83: 18-26
30. Karski JM, Teasdale SJ,NormanP, et al. Prevention of bleedingafter cardiopulmonarybypass with high-dose tranexamic acid. Doubleblind, randomizedclinical trial. J ThoracCardiovasc Surg 1995;110: 835-42
31. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995; 82: 383-92
32. Butterworth J, James RL, Lin Y, Prielipp RC, Hudspeth AS. Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999; 90: 1624-35
33. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107: 1783-90
34. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110: 350-3
35. Mohseni K, Jafari A, Nobahar MR, Arami A. Polymyoclonus seizure resulting fromaccidental injection of tranexamic acid in spinal anesthesia. Anesth Analg 2009; 108: 1984-6
36. Garcha PS, Mohan CV, Sharma RM. Death after an inadvertent intrathecal injection of tranexamic acid. Anesth Analg 2007; 104: 241-2
37. YehHM,LauHP, Lin PL, SunWZ,MokMS.Convulsionsandrefractory ventricular fibrillation after intrathecal injection of a massive dose of tranexamic acid. Anesthesiology 2003; 98: 270-2
38. Martin K, Knorr J, Breuer T, et al. Seizures after open heart surgery: comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Anesth 2011; 25: 20-5
39. Breuer T, Martin K, Wilhelm M, et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg 2009; 35: 167-71
40. Keyl C, Uhl R, Beyersdorf F, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg 2011; 39: e114-21
41. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg 2012; 93: 148-54
42. Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth 2012; 59: 6-13
43. BermanM, Cardone D, Sharples L, et al. Safetyand efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. Ann Thorac Surg 2010; 90: 1432-6
44. Lecker I,Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122: 4654-66
45. Umlas J. Fibrinolysis and disseminated intravascular coagulation in open heart surgery. Transfusion 1976; 16: 460-3
46. TanakaK, TakaoM,YadaI,YuasaH,KusagawaM,DeguchiK. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989; 3: 181-8
47. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13
48. Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg 2010; 37: 1375-83
49. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110: 21-9
50. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von HeymannC. Mortalityassociated withadministrationof high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010; 14: R148
51. Later AF, Maas JJ, Engbers FH, et al. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial. Eur J Cardiothorac Surg 2009; 36: 322-9
52. Greilich PE, Jessen ME, Satyanarayana N, et al. The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebocontrolled, noninferiority trial. Anesth Analg 2009; 109: 15-24
53. Pasquali SK, Li JS, He X, et al. Comparative analysis of antifibrinolytic medications in pediatric heart surgery. J ThoracCardiovasc Surg 2012; 143: 550-7
54. Shimizu K, Toda Y, Iwasaki T, et al. Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial. J Anesth 2011; 25: 823-30
55. Martin K, Breuer T, Gertler R, et al. Tranexamic acid versus varepsilon-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. Eur J Cardiothorac Surg 2011; 39: 892-7
56. Martin K, Gertler R, Liermann H, et al. Switch from aprotinin to epsilon-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery. Br J Anaesth 2011; 107: 934-9
57. Martin K, Gertler R, Macguill M, et al. Replacement of aprotinin by {varepsilon}-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome. Br J Anaesth 2013; 110: 615-21
58. Cheng DC, Bainbridge D, Martin JE, Novick RJ. Does off-pump coronaryarterybypass reduce mortality, morbidity,andresource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology 2005; 102: 188-203
59. Kon ZN, Kwon MH, Collins MJ, et al. Off-pump coronary artery bypass leads to a regional hypercoagulable state not detectable using systemic markers. Innovations (Phila) 2006; 1: 232-8
60. Raja SG, Akhtar S. Hypercoagulable state after off-pump coronary artery bypass grafting: evidence, mechanisms and implications. Expert Rev Cardiovasc Ther 2011; 9: 599-608
61. Grant MC, Kon Z, Joshi A, et al. Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass. Ann Thorac Surg 2008; 86: 815-22; discussion 815-22
62. Desai PH, Kurian D, Thirumavalavan N, et al. A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery. Anesth Analg 2009; 109: 1387-94
63. Adler Ma SC, Brindle W, Burton G, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011; 25: 26-35
64. Wang G, Xie G, Jiang T, et al. Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesth Analg 2012; 115: 239-43
65. Weber CF, Gorlinger K, Byhahn C, et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol 2011; 28: 57-62
66. Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point- of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, singlecenter cohort study. Anesthesiology 2011; 115: 1179-91
67. MaegeleM, Lefering R,Yucel N, et al.Earlycoagulopathyin multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38: 298-304
68. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55: 39-44
69. Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65: 748-54
70. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792-7
71. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67: 125-31
72. Tauber H, Innerhofer P, Breitkopf R, et al. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth 2011; 107: 378-87
73. Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113: 1003-12
74. Brenni M,Worn M, Bruesch M, Spahn DR, Ganter MT. Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand 2010; 54: 111-7
75. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32
76. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-101
77. Roberts I, Shakur H, Ker K, Coats T. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011; 1: CD004896
78. Effect of tranexamic acid in traumatic brain injury:a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). Br Med J 2011; 343: d3795
79. Rossaint R, Bouillon B, Cerny V, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14: R52
80. Tzortzopoulou A, Cepeda MS,SchumannR,Carr DB. Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev 2008; 3: CD006883
81. Wong J, El Beheiry H, Rampersaud YR, et al. Tranexamic acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg 2008; 107: 1479-86
82. Dhawale AA, Shah SA, Sponseller PD, et al. Are antifibrinolytics helpful in decreasing blood loss and transfusions during spinal fusion surgery in children with cerebral palsy scoliosis? Spine 2012; 37: E549-55
83. Verma K, Errico TJ, Vaz KM, Lonner BS. A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery. BMC Surg 2010; 10: 13
84. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105: 1034-46
85. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009; 123: 687-96
86. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581-6
87. Roullet S, Pillot J, Freyburger G, et al. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J Anaesth 2010; 104: 422-8
88. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000; 355: 1303-9
89. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91: 29-34
90. Dalmau A, Sabate A, Koo M, et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl 2004; 10: 279-84
91. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007; 7: 185-94
92. Massicotte L, Denault AY, Beaulieu D, Thibeault L, Hevesi Z, Roy A. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 2011; 91: 1273-8
93. Ickx BE, van der Linden PJ, Melot C, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 2006; 46: 595-605
94. Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 2011; 12: CD009052
95. Warnaar N, Mallett SV, Klinck JR, et al. Aprotinin and the risk of thromboticcomplicationsafter liver transplantation:a retrospective analysis of 1492 patients. Liver Transpl 2009; 15: 747-53
96. Trzebicki J, Flakiewicz E, Kosieradzki M, et al. The use of thromboelastometry in the assessment of hemostasis during orthotopic liver transplantation reduces the demand for blood products. Ann Transplant 2010; 15: 19-24
97. Gorlinger K. Coagulation management during liver transplantation. Hamostaseologie 2006; 26: S64-76
98. Wu CC,Ho WM,Cheng SB, et al.Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy. Ann Surg 2006; 243: 173-80
99. Ronsmans C, GrahamWJ. Maternal mortality: who, when, where, and why. Lancet 2006; 368: 1189-200
100. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006- 2008.Theeighth report of theconfidential enquiries intomaternal deaths in the United Kingdom. BJOG 2011; 118 (Suppl. 1): 1-203
101. Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarean section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112: 154-7
102. Ferrer P, Roberts I, Sydenham E, Blackhall K, Shakur H. Antifibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth 2009; 9: 29
103. Gohel M, Patel P, Ashoo G, Desai P. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. J Obstet Gynaecol India 2007; 57: 227-30
104. Yang H, Zheng S, Shi C. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood loss: a randomized, comparative, multicenter trial.Zhonghua Fu Chan Ke Za Zhi 2001;36:590-2
105. Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010; 7: CD007872
106. Ducloy-Bouthors AS, Jude B, Duhamel A, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Critical Care 2011; 15: R117
107. Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011; 28: 233-40
108. Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11: 40
109. Rosenorn J, Eskesen V, Schmidt K, Ronde F. The risk of rebleeding from ruptured intracranial aneurysms. J Neurosurg 1987; 67: 329-32
110. Starke RM, Connolly ES Jr. Rebleeding after aneurysmal subarachnoid hemorrhage. Neurocritical Care 2011; 15: 241-6
111. Roos YB, Rinkel GJ,VermeulenM, AlgraA, vanGijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; 2: CD001245
112. Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomizedplacebo-controlled trial.STARStudyGroup.Neurology 2000; 54: 77-82
113. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002; 97: 771-8
114. Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008; 39: 2617-21
115. Harrigan MR, Rajneesh KF, Ardelt AA, FisherWS III. Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, andhydrocephalus. Neurosurgery 2010; 67: 935-9; discussion 9-40